Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $117.30

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $117.30.

Several research analysts have recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a report on Monday, March 9th. Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a report on Monday, March 9th. Wells Fargo & Company started coverage on shares of Dianthus Therapeutics in a research report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Finally, Truist Financial raised their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 9th.

Dianthus Therapeutics Trading Down 1.0%

DNTH stock opened at $78.55 on Friday. The stock’s 50 day simple moving average is $58.13 and its 200 day simple moving average is $45.50. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $88.02. The stock has a market capitalization of $3.49 billion, a PE ratio of -19.16 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. On average, research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Simrat Randhawa sold 33,830 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 200,430 shares of company stock valued at $16,332,702. Insiders own 16.56% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics during the second quarter valued at about $27,000. Parkside Financial Bank & Trust raised its stake in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $40,000. Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.